Millions of European women navigating menopause may soon see a shift in their treatment plans. The European Society of Endocrinology (ESE) has released a major new clinical practice guideline, urging doctors across the continent to adopt a “holistic approach” to midlife health and, critically, to reconsider the way they prescribe hormone therapy to reduce the risk of stroke and breast cancer associated with menopausal hormone therapy (MHT), while recommending safer alternatives for high-risk patients.
The comprehensive guideline, “ European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause ,” published recently in the European Journal of Endocrinology , emphasizes that while Menopausal Hormone Therapy (MHT) is highly effective for severe symptoms like hot flashes and night sweats, the method of delivery is key to patient safety. The guidance is particularly pointed for high-risk patients: Women with a history of migraine aura are already at a higher baseline risk for stroke.
For this group, the ESE strongly suggests transdermal estrogen due to its proven superior cardiovascular safety profile compared to oral forms.
The document emphasizes treating the person beyond menopausal symptoms and reexamines how hormone therapy is prescribed to align with cardiovascular safety and cancer risk considerations.
The guidance appears in the European Journal of Endocrinology and aims to standardize evaluation and management across Europe.
The guideline reiterates that menopausal hormone therapy (MHT) remains highly effective for severe vasomotor symptoms such as hot flashes and night sweats, but it stresses that the route of administration materially influences risk profiles.
The guideline notes that standard oral hormone treatments are associated with an increased risk of ischemic stroke relative to other delivery methods.
In response, the ESE endorses transdermal estradiol as the preferred modality for appropriate candidates, particularly highlighting its neutral effect on stroke risk and its comparatively safer cardiovascular profile versus oral regimens.
For these individuals, the guideline strongly favors transdermal estrogen delivery, citing its superior cardiovascular safety relative to oral options.
This emphasis on high-risk patients is presented as a crucial refinement to general practice, signaling a shift away from default oral formulations in selected populations.
This approach is portrayed as having a neutral effect on stroke risk, in contrast to oral regimens.
The document underscores that the choice of delivery must be individualized, balancing symptom burden, risk factors, and patient preferences.
Clinicians are urged to consider diet, physical activity, and mental health as integral components of management, rather than focusing solely on hormone replacement therapy.
This reflects a shift toward comprehensive lifestyle optimization as a foundational aspect of perimenopausal and postmenopausal care.
It instructs clinicians to consider Premature Ovarian Insufficiency (POI) in women under 40 presenting with irregular periods, subfertility, or classic menopausal symptoms.
Biochemical testing is recommended for this younger cohort, and there is an emphasis on prompt referral to a specialized menopause expert or multidisciplinary team, especially for patients with complex medical histories or high cancer-risk profiles.
Acknowledging that lifetime breast cancer risk in Western populations exceeds 10% according to major cancer surveillance bodies, the guideline frames informed consent as essential to the prescribing process.
The emphasis on transparent risk communication is presented as a non-negotiable element of patient-centered care.
However, the source document does not provide numerical outcome data within this summary, nor does it reveal new trial results beyond the stated safety associations and recommendations.
The extent to which these recommendations have been validated across diverse European populations or in subgroups beyond migraine with aura is not detailed in the provided content.
It supports a move toward transdermal routes when appropriate, while encouraging a broadened care plan that integrates lifestyle factors and multidisciplinary input for POI and high-risk cases.
The emphasis on informed consent and risk disclosure is positioned as a practical non-negotiable step in shared decision-making.